Drug Search Results
Using advanced filters...
Advanced Search [+]

Trichostatin a

Alternative Names: trichostatin a, a 300, tsa, VTR-297, VTR297, VTR 297
Latest Update: 2025-04-18
Latest Update Note: News Article

Product Description

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Bangladesh | Brazil | Colombia | Dominican Republic | Ecuador | France | Germany | Italy | Mexico | Peru | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: Arbutus Biopharma
Company Location: BURNABY A1 V5J 5J8
Company CEO: William Collier
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Osteoarthritis|Rotator Cuff Injuries|Arthritis, Infectious|Skin Diseases, Infectious

Phase 2: Biliary Tract Cancer

Phase 1: Melanoma|Colorectal Cancer|Oncology Hematological Unspecified|Oncology Unspecified|Pinealoma|Rhabdoid Tumor|Intestinal Diseases|Medulloblastoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IMPACT

P1

Recruiting

Medulloblastoma|Pinealoma|Rhabdoid Tumor

2030-12-29

ChiCTR2400085261

N/A

Not yet recruiting

Osteomyelitis

2026-12-31

NEAR-TSA

N/A

Recruiting

Autism Spectrum Disorder

2026-08-24

IHS

N/A

Recruiting

Migraine Disorders

2026-01-01

Recent News Events